Erratic chief's exit may restart IPO process, but removing him may not solve the office-sharing company's biggest problem.
Updated: 09/24/2019 07:16P
There is an opportunity for biotech-style rewards hiding in an unexpected place: big pharma. Bristol-Myers Squibb and Celgene are set to close their $74 billion ...
Updated: 09/24/2019 04:23P